Online inquiry

IVTScrip™ mRNA-Anti-Canlupfam CD52, AT-005(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3375MR)

This product GTTS-WQ3375MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets Canlupfam CD52 gene. The antibody can be applied in Canine T-cell lymphoma research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Caninized
RefSeq NM_001003240.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 403918
UniProt ID Q28896
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Canlupfam CD52, AT-005(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ3375MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ1813MR IVTScrip™ mRNA-Anti-CFD, AFD Anti-fD(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AFD Anti-fD
GTTS-WQ5866MR IVTScrip™ mRNA-Anti-CD40, CHIR-12,12(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CHIR-12,12
GTTS-WQ14872MR IVTScrip™ mRNA-Anti-SLC39A6, SGN-LIV1A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA SGN-LIV1A
GTTS-WQ5989MR IVTScrip™ mRNA-Anti-ITGAV&ITGB3, CNTO 095(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CNTO 095
GTTS-WQ9923MR IVTScrip™ mRNA-Anti-EPHA3, KB-004(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA KB-004
GTTS-WQ15413MR IVTScrip™ mRNA-Anti-HAVCR2, TSR-022(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA TSR-022
GTTS-WQ13805MR IVTScrip™ mRNA-Anti-S, REGN-10933(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA REGN-10933
GTTS-WQ4049MR IVTScrip™ mRNA-Anti-IL36RN, BI 655130(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BI 655130
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW